PaxVax inks Swiss marketing and distribution agreement with Seqirus for influenza vaccines
![](/46/pdcnewsitem/04/25/51/paxvax.png)
With the addition of Agrippal and Fluad, PaxVax is building a robust portfolio of vaccines for the Swiss market.
PaxVax has entered into a marketing and distribution agreement with Seqirus. Under the terms of this agreement, PaxVax will market, sell and distribute two of Seqirus’ influenza vaccine products - Agrippal (surface antigen, inactivated) and Fluad (influenza vaccine, adjuvanted) - in Switzerland.
“PaxVax has deep expertise in the vaccine industry and has built a substantial global marketing, sales and distribution network that enables us to support vaccine makers serving major markets in North America and Europe,” said Nima Farzan, President and CEO of PaxVax. “We are pleased to partner with Seqirus, which is the second largest influenza vaccine manufacturer in the world, to ensure the availability of these important vaccines. With the addition of Agrippal and Fluad, PaxVax is building a robust portfolio of vaccines for the Swiss market that includes our own typhoid vaccine, Vivotif.”
Agrippal is an inactivated trivalent influenza virus vaccine indicated for adults and children older than 6 months. Fluad is an adjuvanted trivalent inactivated influenza vaccine indicated for adults 65 years and older.
PaxVax has established legal entities and commercial infrastructure to support its products in the US, Italy, Portugal, Spain, Switzerland and the UK. In addition to its partnership with Seqirus, the company also markets and distributes Valneva’s travel vaccines in Italy, Spain and Portugal.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance